Business Wire

MA-QUANTORI

8.9.2021 06:02:11 CEST | Business Wire | Press release

Share
Quantori Strengthens Global Leadership Team, Names Senior Business Leader Solman Rahman as Executive Vice President, Europe

Quantori , a leading global provider of end-to-end software engineering, scientific informatics, data sciences and digital transformation services for life science and healthcare companies, today announced the appointment of Solman Rahman to Executive Vice President, Europe to support Quantori’s aggressive growth strategy and strengthen its market position as a premier global services provider.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005840/en/

“Solman’s wealth of experience in building and scaling business operations for leading technology consulting and digital platform engineering companies serving the European life science and healthcare markets makes him uniquely positioned to lead Quantori’s expansion in this key region,” said Richard Golob, CEO, Quantori. “Europe continues to be a powerhouse of world-class life science and biopharma industry innovation. We look forward to working with Solman in developing strategic client relationships to help biopharma and life science companies deliver critical technology programs and data management imperatives to accelerate development of novel therapeutics."

As Quantori’s Executive Vice President for Europe, Solman will be responsible for developing key partnerships within the EU region’s ecosystem of pharma and healthcare companies, in addition to ensuring delivery of superior services and providing leading technology capabilities to Quantori’s clients. Solman joins Quantori from EPAM Systems where he led the Northern Europe business and where he previously worked with Quantori leadership, including Richard Golob, who led EPAM’s Global Life Sciences Business into the fastest growing unit at EPAM, in addition to Dr. Yuriy Gankin, Quantori’s Chief Scientific Officer, and Vitaliy Aronov, Quantori’s Chief Technology Officer.

“I am thrilled to be rejoining such a brilliant executive team at a very exciting time in Quantori’s growth and development, especially as the European biopharma industry is scaling the use of digital technologies to enable the provision of precision medicines and personalized healthcare,” said Solman. “A major challenge in working with IT outsourcing companies is that they have a limited understanding of the life sciences and healthcare industries. One of Quantori’s key differentiators is its extensive domain knowledge underpinned by true scientific depth. This unique combination enables us to add considerable value from the outset and speed-to-market horsepower to the critical focus of today’s biopharma companies – to accelerate the translation of their research and data insights into a pipeline of new medicines.”

Prior to leading EPAM’s Northern European business, Solman worked at Cognizant in several roles, including serving as Head of Strategic Engagements and Industry Practice leadership. Solman began his career as an analyst at Cowen Inc. in the Technology Investment Banking Group, undertaking equity research in the biopharma and high-tech sectors. He currently serves as a board advisor to Conversationly, a digital agency leveraging messaging, automation and AI technologies to promote conversational commerce. He holds MSc and BSc degrees in Economics & Management and Econometrics from the London School of Economics and Political Science.

“We are thrilled to welcome Solman onboard, and he will be instrumental in our efforts to expand operations in Europe to help biopharma leaders bring novel and life-saving therapies to market through the powerful partnership of digital IT and R&D informatics,” said Yuriy Gankin, PhD, Quantori’s Chief Scientific and Strategy Officer.

About Quantori
Quantori is transforming life sciences and healthcare through the power of digital IT. Quantori develops end-to-end software engineering, scientific informatics, and data science solutions that help biopharma companies accelerate every stage of drug discovery and development. Quantori combines data engineering and advanced analytics with deep scientific domain knowledge to enable life science and healthcare organizations to achieve their digital transformations with greater speed and agility. Learn more about Quantori at www.quantori.com and connect on social media @Twitter , @LinkedIn , and Facebook .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye